AstraZeneca Strengthens Metabolic Diseases, Pays .2 Billion to Partner on CSPC Anti-Obesity, Diabetes Drugs

AstraZeneca Strengthens Metabolic Diseases, Pays $1.2 Billion to Partner on CSPC Anti-Obesity, Diabetes Drugs

AstraZeneca expands its perspectives in cardiometabolic diseases, paying 1.2 billion dollars initiate a partnership on eight programs that include anti-obesity drug candidates with potential advantages over currently available products and …

AstraZeneca Strengthens Metabolic Diseases, Pays $1.2 Billion to Partner on CSPC Anti-Obesity, Diabetes Drugs Read More